ERIS Lifescience

ERIS16 Apr 2024
Pharmaceuticals
+13.30 (+1.56%)
Lowest Today
Highest Today
Today’s Open
Prev. Close
52 Week High
52 Week Low
To Invest in ERIS Lifescience
ERIS Lifescience
Pharmaceuticals
ERIS16 Apr 2024
+13.30 (+1.56%)
OverviewFundamentals
1D
1M
6M
1Y
5Y
All

ERIS Lifescience - Share Price & Details

Lowest Today
840.05
Highest Today
871.2
Today’s Open
840.05
Prev. Close
854.3
52 Week High
971
52 Week Low
596.15
Traded Volume
Market Cap(Cr)
Avg Traded Price
1 Year return
41.73%
Upper Circuit
Lower Circuit
P/E TTM
33.92
P/B Ratio
4.81
Traded Value(Cr)
0.00
EPS TTM
25.58
Book value
Dividend
0.85%

Price Performance

2.70 %
1 Wk
2.65 %
1 M
-4.14 %
3 M
41.73 %
1 Y
-4.15 %
YTD

Traded Volume Movement

Technical Details

Support 3
829
Support 2
838
Support 1
853
Pivot Point :
862
Resistance 1
877
Resistance 2
886
Resistance 3
901

Reports

Peer Comparison

Scrip NamePriceDaily ChangeM.Cap (Cr)1 Year Returns %P/E (TTM)PB Ratio
ERIS Lifesciences Ltd
₹867.60(+13.30/1.56%)
867.60+13.3011,803.4841.7333.924.81
Astrazeneca Pharma India Ltd
₹5,288.60(+96.20/1.85%)
5,288.60+96.2013,221.5065.0282.8920.19
Bliss GVS Pharma Ltd
₹112.15(+2.00/1.82%)
112.15+2.001,174.1151.8217.201.20
Cipla Ltd
₹1,376.05(-5.20/-0.38%)
1,376.05-5.20111,097.7451.7233.784.29
Abbott India Ltd
₹26,091.35(-97.95/-0.37%)
26,091.35-97.9555,444.1215.7748.4017.83
Amrutanjan Health Care Ltd
₹648.60(-9.30/-1.41%)
648.60-9.301,875.149.2142.617.16

About ERIS Lifesciences Ltd

ERIS Lifesciences Ltd is in the Pharmaceuticals sector, having a market capitalization of Rs. 11803.48 crores. It has reported a sales of Rs. 315.96 crores and a net profit of Rs. 31.66 crores for the quarter ended December 2018. The company management includes Amit Indubhushan Bakshi, Amit Indubhushan Bakshi,Kaushal Kamlesh Shah,Inderjeet Singh Negi,Krishnakumar Vaidyanathan,Sujesh Vasudevan,Prashant Gupta,Rajeev Narotam Dalal,Kalpana Unadkat (ERIS Lifesciences Ltd) among others.
Chairman
Amit Indubhushan Bakshi
Registered office
8th Floor Commerce House -IV,Prahladnagar 100 FT Road,Ahmedabad,Gujarat,380015
FAX :91-79-48903474
Background
Incorporation Year2007
Face Value₹1
Market Lot1

Latest News

BSE Power Index outperforms Sensex by 3X since 2021
The BSE Power index extended its outperformance over the Sensex to the fourth consecutive year on a surge in investments in the power sector. Since 2021 the BSE Power Index has given a return of 147 percent against Sensex’s 48 percent return during the same period, giving a threefold return over the benchmark index. BSE Power Index hit a record high on April 4 at 7,112.42.
17 Apr 2024 | 02:30 PM
India Ratings upgrades Sunteck Realty to ‘IND AA’
Ratings agency India Ratings and Research (Ind-Ra) has upgraded realty developer Sunteck Realty’s Long-term Issuer Rating to ‘IND AA’ from ‘IND AA-’. The Outlook is Stable.The ratings factor in the strong operational performance that the developer has displayed since 2020-21, and consequent improvement in the scale of operations.Post 2020-21.
17 Apr 2024 | 06:53 PM
Adani group infuses Rs 8,339 cr more into Ambuja Cements
The Adani family, the promoters of Ambuja Cements, have infused an additional Rs 8,339 crore into the cements company under the warrants program, increasing its stake in the company to 70.3 percent and total investment to Rs 20,000 crore, according to an exchange filing issued on April 17 . The family had invested Rs 5,000 crore in October 2022, Rs 6,661 crore on 28 March 2024.
17 Apr 2024 | 06:25 PM
EV pacts charge up Nomura's target price on Exide as shares surge 51%
Nomura has increased Exide Industries' target price to Rs 485 from Rs 233 after considering the battery maker's agreement with Hyundai India Motor Ltd and Kia India Pvt Ltd.  The new target price by Nomura indicates an upside of over 3 percent from the Exide's closing price on April 16. Nomura has maintained its 'Buy' rating on Exide. Exide's shares has increased by 25 percent.
17 Apr 2024 | 06:08 PM
SBI Securities recommends this small finance bank stock
In April, small finance banks (SFBs) demonstrated strength on the stock market, spurred by their business updates for the March quarter, which revealed double-digit growth in both advances and deposits.Brokerage firm SBI Securities has suggests Suryoday Small Finance Bank stock with ‘buy’ recommendation with a target price of  ₹227.8, with an upside potential of over 20 per cent.
17 Apr 2024 | 06:05 PM

How to buy ERIS Lifescience shares on nse?

To buy ERIS Lifescience shares in Motilal Oswal, you just need to open a demat account and get your KYC documents verified

What is the ERIS Lifescience share price today?

The ERIS Lifescience shares price on nse is Rs.867.6 today.

What is the market cap of ERIS Lifescience shares on BSE ?

The company has a market capitalization of Rs.11803.48Cr

What is the PE & PB ratio of ERIS Lifescience shares ?

PE is 33.92 and PB is 4.81

What is the 52 Week High and Low of ERIS Lifescience shares?

ERIS Lifescience stock price high: Rs.971 ERIS Lifescience stock price low: Rs.596.15

What is the price of ERIS Life Sciences stocks on BSE?

The price of ERIS Life Sciences as of the end of day 17th April 2023 was INR 612.6 on BSE.

Is it safe to buy ERIS Life Sciences?

ERIS Life Sciences net profit has increased from Rs. 291.15 crores to Rs. 405.79 crores in the last four years. And the company's sales revenue has grown from Rs.982.6 crores to Rs. 1347 crores in the last four years. 

ERIS Life Sciences stock 52 weeks low is Rs.551.3 and high is Rs.749.8.

Equity investment is a risk like any other investment and it is advisable to take professional advice before investing.  

 

What is the current market value per stock of ERIS Life Sciences?

The current market value (or market capitalization) of ERIS Life Sciences is approximately Rs. 8.33K crores as on 17th April 2023.

Does ERIS Life Science have any debts?

ERIS Life Sciences has a debt-to-equity ratio of 0.13.  

 

Will ERIS Life Science stock price increase?

Eris Life Sciences is a pharmaceutical company based in India that focuses on developing, manufacturing, and marketing branded pharmaceutical products across various therapeutic areas. The company's products are sold in India and other countries, including Nepal, Sri Lanka, and Mauritius.

However, it is near impossible to predict the future movements of stock prices, as they are linked to a wide range of variables, including market trends, economic conditions, company performance, and global events.

It's imperative to conduct thorough research and due diligence in making any investment decisions. And to consider several relevant factors that could impact the company's future prospects.

 

Should I buy or sell ERIS Life Science?

ERIS Life Sciences stock has given a positive return of 33.61%  over the last 3 years and a negative return of -12.85% over the past 12 months.  

Selling or buying of specific stock or stocks depends on your personal financial goals and risk tolerance.